Content Status
Type
Linked Node
Management of DR-TB ADR: Giddiness
Learning Objectives- Discuss Giddiness as an ADR to DR-TB Treatment, suspected agent.
- Enumerate suggested management strategies for Giddiness.
H5Content
Content
Adverse Drug Reaction (ADR), such as giddiness, may occur from the Drug-resistant TB (DR-TB) treatment regimen.
Suspected agent(s) - Amikacin (Am), Ethionamide (Eto), Fluoroquinolone (FQ) and/or Pyrazinamide (Z)
Suggested Management Strategies
- Whenever a patient complains of giddiness, over-sleepiness or poor concentration, they should be provided counselling.
- If severe, the offending drug should be identified by administering drugs individually and observing the response.
- The dose of the offending drug identified may be adjusted or the offending drug terminated if required.
- Aminoglycosides, especially in the elderly age group must be kept in mind for giddiness as it may be an early sign of 8th nerve toxicity.
Point to Note: In cases of severe giddiness, the patient may be referred to the neurologist for further management as per the standard protocols.
Resources
LMS Page Link
Content Creator
Reviewer
Target Audience
- Log in to post comments